Who is sponsoring NCT04735848?

NCT04735848 is sponsored by Pierre-Alexandre Krayenbuehl.

What drugs are being tested in NCT04735848?

Interventions in NCT04735848: Iron-supplement application.

What condition does NCT04735848 study?

NCT04735848 studies Iron Deficiency (Without Anemia).

Is NCT04735848 still recruiting?

NCT04735848 is currently completed. Last updated 8 October 2021.

Last reviewed 2021-10-08 · How we verify

NCT04735848

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasma Hepcidin Response to Differently Dosed Iron Supplements

Completed NA Last updated 8 October 2021

What this trial tests

NA trial testing Iron-supplement application in Iron Deficiency (Without Anemia) in 15 participants. Completed in 31 August 2021.

Timeline

1 June 2021

Primary endpoint
31 August 2021

31 August 2021

Quick facts

Lead sponsor	Pierre-Alexandre Krayenbuehl
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	15
Start date	1 June 2021
Primary completion	31 August 2021
Estimated completion	31 August 2021
Sites	1 location across Switzerland

Drugs / interventions tested

Iron-supplement application

Conditions studied

Iron Deficiency (Without Anemia) — all drugs for Iron Deficiency (Without Anemia) →

Sponsor

Pierre-Alexandre Krayenbuehl

Who can join

18 and older, female only, with Iron Deficiency (Without Anemia). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study participants will take 3 different doses of iron supplements at 8 am, on 3 different days. By taking blood samples in the morning and afternoon, the investigators will determine the effects of the iron supplements on plasma hepcidin and compare them to baseline plasma hepcidin values.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The magnitude of the plasma hepcidin response to oral iron supplements depends on the iron dosage.
Karczewski M, Simic S, Saleh L, Nowak A, et al · · 2024 · cited 1× · PMID 38579297 · DOI 10.57187/s.3635

Verify or expand the search:

Other recruiting trials for Iron Deficiency (Without Anemia)

Currently open trials in the same condition.

NCT06822062 — Effect of Chitin and Ascorbic Acid on Dietary Insect Iron Absorption · NA · recruiting
NCT06990373 — Iron Status of Non-anemic Pregnant Women in First Trimester · recruiting
NCT07083492 — Non-invasive Detection of Iron Deficiency in Obstetrics · recruiting
NCT05500014 — Effect of Altitude on Iron Absorption in Iron Depleted Women · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04735848 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pierre-Alexandre Krayenbuehl
Last refreshed: 8 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04735848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing